Rekah Pharmaceutical Industry Ltd
TASE:REKA
Rekah Pharmaceutical Industry Ltd
Operating Income
Rekah Pharmaceutical Industry Ltd
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Operating Income
₪2.9m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-17%
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Operating Income
$3.6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-1%
|
|
Taro Pharmaceutical Industries Ltd
NYSE:TARO
|
Operating Income
$22m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-25%
|
|
I
|
InterCure Ltd
TASE:INCR
|
Operating Income
₪34.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Mediwound Ltd
NASDAQ:MDWD
|
Operating Income
-$15.5m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-7%
|
|
C
|
Cannassure Therapeutics Ltd
TASE:CSURE
|
Operating Income
-₪2.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Rekah Pharmaceutical Industry Ltd's Operating Income?
Operating Income
2.9m
ILS
Based on the financial report for Dec 31, 2023, Rekah Pharmaceutical Industry Ltd's Operating Income amounts to 2.9m ILS.
What is Rekah Pharmaceutical Industry Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-17%
Over the last year, the Operating Income growth was -78%. The average annual Operating Income growth rates for Rekah Pharmaceutical Industry Ltd have been -48% over the past three years , -29% over the past five years , and -17% over the past ten years .